Tag
This study reveals that midlife plasma p-tau181 predicts faster memory decline over 11 years, highlighting a long prodromal phase of Alzheimer’s disease. Late-life biomarkers p-tau181, NfL, and GFAP correlate with accelerated cognitive decl
This study clarifies that cervical cord atrophy in MS is partly disease-specific beyond aging effects, with distinct patterns linked to age and disease onset, correlating with disability and neurodegeneration markers.
This longitudinal study investigates plasma biomarker dynamics in Alzheimer’s patients treated with lecanemab, revealing distinct biomarker trajectories that reflect amyloid clearance, tau modulation, and immune responses, offering in
This review explores evidence linking smoking and exhaled carbon monoxide levels to reduced Parkinson’s disease risk, emphasizing a potential protective role of carbon monoxide, supported by recent large-scale cohort data and biologic
Advanced MRI analyses identify three biologically distinct subtypes of white matter hyperintensities (WMHs), linking specific lesion evolution patterns with neurodegeneration and vascular/metabolic risks, offering refined insights into cere
This review explores the role of dysregulated iron metabolism and inflammation, particularly elevated serum ferritin, in isolated REM sleep behavior disorder (iRBD) as a prodromal stage of neurodegeneration, synthesizing recent longitudinal
Automated speech analysis of brief connected speech accurately identifies clinical, anatomical, and neuropathological variants of primary progressive aphasia, facilitating scalable diagnosis and monitoring.
This review synthesizes international evidence on survival in genetic frontotemporal dementia (FTD), highlighting key predictors such as age at onset, clinical phenotype, and motor symptoms, and discusses implications for patient care and t
This study unveils tofersen’s distribution and potent SOD1 reduction within the CNS of SOD1-ALS patients, utilizing autopsy tissues from clinical trial participants, confirming anticipated pharmacokinetic and pharmacodynamic effects.
A phase 3 randomized, placebo-controlled crossover trial demonstrates that levacetylleucine significantly improves neurological function in ataxia-telangiectasia patients with a favorable safety profile.
This review synthesizes current evidence on CSF TMEM106B levels in FTLD, highlighting their associations with disease severity, genetic variants, brain atrophy, and clinical progression, emphasizing TMEM106B’s potential as a biomarker
GI biopsies reveal misfolded proteins years before neurological symptoms appear, offering a new biomarker for early neurodegenerative disease prediction and intervention.
The Phase 2b PARADIGM trial demonstrates that PrimeC—a novel combination of celecoxib and ciprofloxacin—is safe and significantly slows functional decline in ALS patients over 18 months, offering new hope for multi-target neuroprotective st
Recent evidence from a large-scale Swedish study reveals that long-term exposure to fine and coarse particulate matter and nitrogen dioxide significantly increases the risk of Motor Neuron Disease and accelerates functional decline and mort
The Phase 2b PARADIGM trial reveals that PrimeC, a novel oral combination therapy, is safe and significantly slows functional decline and reduces the risk of death or hospitalization in ALS patients over 18 months.
This study identifies somatic gene mutations in excitatory neurons of the motor cortex as a potential driver of sporadic ALS, challenging the traditional view of the disease’s genetic origins.
This retrospective study identifies a high prevalence of spinal cord p-tau and protein copathologies in patients with Chronic Traumatic Encephalopathy (CTE), suggesting the existence of a ‘trauma-related encephalomyelopathy’ lin
A landmark autopsy study reveals that Chronic Traumatic Encephalopathy (CTE) involves extensive spinal cord pathology, including tau, TDP-43, and amyloid-β deposits. These findings suggest that repetitive head impacts trigger a widespread e
Research indicates that circulating levels of the longevity protein klotho can moderate the relationship between cerebral atrophy and cognitive performance in older adults, suggesting a biological mechanism for cognitive resilience even in
A comprehensive multi-cohort proteomic study identifies Oligodendrocyte Myelin Glycoprotein (OMG) as a causal biomarker for neurodegenerative resiliency, linking its peripheral abundance to axonal integrity and reduced risk of dementia and
